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Abstract
Ovarian clear-cell carcinoma (OCCC) is an aggressive form of ovarian cancer with high ARID1A 
mutation rates. Here we present a mutant mouse model of OCCC. We find that ARID1A 
inactivation is not sufficient for tumor formation, but requires concurrent activation of the 
phosphoinositide 3-kinase catalytic subunit, PIK3CA. Remarkably, the mice develop highly 
penetrant tumors with OCCC-like histopathology, culminating in hemorrhagic ascites and a 
median survival period of 7.5 weeks. Therapeutic treatment with the pan-PI3K inhibitor, 
BKM120, prolongs mouse survival by inhibiting tumor cell growth. Cross-species gene expression 
comparisons support a role for IL-6 inflammatory cytokine signaling in OCCC pathogenesis. We 
further show that ARID1A and PIK3CA mutations cooperate to promote tumor growth through 
sustained IL-6 overproduction. Our findings establish an epistatic relationship between SWI/SNF 
chromatin remodeling and PI3K pathway mutations in OCCC and demonstrate that these 
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pathways converge on pro-tumorigenic cytokine signaling. We propose that ARID1A protects 
against inflammation-driven tumorigenesis.
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Introduction
Epithelial ovarian cancer (EOC) ranks as the 5th leading cause of cancer death among 
women1. EOC consists of four major histologic tumor subtypes (serous, clear-cell, 
endometrioid, or mucinous) and originates from the coelomic epithelium, which is the 
precursor to the ovarian surface epithelium (OSE) and Müllerian ductal epithelium2. The 
salpinge or fallopian tube of the Müllerian epithelial anlage is the more definitive source of 
serous EOC3. Endometriotic explants originating from more distal sites in the Müllerian 
epithelial anlage may have some propensity to give rise to clear cell or endometrioid EOC in 
humans, but this alternate mechanism of pathogenesis has not been thoroughly 
investigated4, 5.
In addition to histologic feature, each EOC subtype can be further classified into two distinct 
groups on the basis of disease progression, metastatic potential, and molecular signature, 
with low-grade serous, clear-cell, mucinous and endometrioid subtypes being classified as 
Type I tumors and the high-grade serous subtype as Type II tumors6. In general, Type I 
tumors account for up to 25% of EOCs, are genomically stable and have lower metastatic 
potential than Type II tumors, which constitute most of the remaining EOC cases6. In 
addition, KRAS, BRAF, PIK3CA, PTEN, and CTNNB1 (β-CATENIN) mutations have 
historically been associated with Type I tumors at varying frequencies, whereas Type II 
tumors are largely defined by high frequency TRP53 (p53) mutations and chromosome 
instability6, 7, 8. Therefore, EOC consists of a heterogeneous group of cancers, each with 
unique clinical challenges and biology.
Ovarian clear-cell carcinoma (OCCC) is the most common Type I tumor, accounting for 5–
25% of all EOC cases, with incidence varying between populations9, 10, 11. Endometriosis is 
recognized as a significant risk factor for OCCC12, 13, 14. Among all EOC subtypes, OCCC 
has the worst prognosis if diagnosed at an advanced stage of disease because of poor 
response rates to platinum-based chemotherapy9, 10, 15, 16. Consequently, survival rates for 
women with advanced stage OCCC are low9, 10, 15, 16. Although OCCC is the second 
leading cause of death from ovarian cancer, the etiology and pathogenesis of this devastating 
disease are poorly understood.
Recent genome sequencing efforts support a strong genetic contribution to OCCC etiology 
based upon the discovery of high frequency (up to 50%) ARID1A tumor mutations17, 18. 
ARID1A is also somatically mutated in another Type I EOC, endometrioid carcinoma, and 
several other gynecologic cancers, including uterine clear-cell and endometrioid carcinomas, 
cervical carcinoma, and uterine carcinosarcoma19, 20. Additional tumor sequencing studies 
have detected recurrent ARID1A mutations in several non-gynecologic cancers and, taken 
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together, components of the SWI/SNF complex are mutated in at least 20% of human 
cancer19, 21, 22, 23. ARID1A is a subunit within the SWI/SNF chromatin remodeling 
complex that facilitates target substrate recognition, however, its role in OCCC tumor 
initiation and progression has yet to be fully elucidated24.
Genetically engineered mouse models offer the opportunity to investigate the contribution of 
genetic factors to EOC etiology and pathogenesis25. In this regard, early research using 
mouse models of EOC established causative roles for coexistent mutations in PTEN and 
KRAS or PTEN and WNT/β-CATENIN pathways in endometrioid EOC7, 8. Recently, Guan 
et al. reported a mouse model of endometrioid EOC involving coexistent mutations in PTEN 
and ARID1A26. In this study, we describe a new mouse model that genetically and 
histologically resembles human OCCC and functionally implicates coexistent ARID1A and 
PIK3CA mutations in cancer causation. We further provide new mechanistic insight into 
OCCC pathogenesis by establishing a functional link between coexistent ARID1A-PIK3CA 
mutations and IL-6 signaling.
Results
Generation of a novel Arid1a conditional allele
To establish a functional role for ARID1A mutations in ovarian clear-cell tumorigenesis, we 
generated a novel Arid1a conditional allele (Arid1afl) by inserting loxP sites flanking exons 
5 and 6 in ARID1A (Fig. 1A,B). Arid1a-null embryos die around gastrulation, thus they are 
not amenable to efficient protein extraction27. In light of its early embryonic lethality, we 
monoalleliclly inactivated ARID1A in embryonic tissues (via Sox2Cre28) to verify our 
Arid1afl allele in the whole animal. Using this approach, we observed an expected 50% 
reduction in total protein from whole embryo lysates (Fig. 1C,D). We next sought to 
inactivate ARID1A in the OSE. To do this, we employed the intrabursal Adenovirus CRE-
mediated (AdCRE) recombination system7, 29. Efficient CRE-mediated genetic 
recombination was consistently observed in the OSE and outer epithelial layers of tissues 
confined to the bursal space (Fig. 1F,H,I). We performed a series of intrabursal AdCRE 
injections on two independent cohorts of Arid1afl/fl mice (n=42) and followed them for 
approximately one year. The mice remained tumor-free with no significant changes in 
survival, other than age-related mortality, similar to the phenotypes reported by Guan et 
al.26 (Supplementary Fig. 1). The observation that ARID1A loss does not lead to tumor 
formation supports the notion that ARID1A mutations require additional mutational “hits” in 
the OSE before tumorigenesis can ensue26.
Coexistent ARID1A-PIK3CA mutations initiate ovarian cancer
To explore this further, we focused on the cancer proto-oncogene, PIK3CA 
(Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha or p110α), which 
also has high OCCC mutation rates30, 31. Recently, coexistent ARID1A-PIK3CA mutations 
were reported in gastric cancer32. Additionally, it has been observed that OCCC tumors 
harboring PIK3CA mutations display concomitant loss of ARID1A immunoreactivity, 
raising the possibility that ARID1A and PIK3CA mutations frequently co-occur in OCCC33. 
To understand the degree of mutational co-occurrence, we compared the incidence of 
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ARID1A and/or PIK3CA mutations in available tumor datasets curated in The Cancer 
Genome Atlas (TCGA) to OCCC tumor sequencing data17. We found that the majority of 
cancers carry genetic alterations in one of these genes, however the rate of ARID1A-PIK3CA 
mutational co-occurrence (33%; pval<0.05) is highest in OCCC (Fig. 2A).
PIK3CA tumor mutations often result in an H1047R ‘hotspot’ substitution within the kinase 
domain, generating a catalytically active protein34. PIK3CA amplification also frequently 
occurs in EOC30. To investigate the effect of PIK3CA alterations on ovarian tumorigenesis, 
we used the CRE-inducible (Gt)Rosa26Pik3ca*H1047R allele35 to drive PIK3CAH1047R 
expression from the Rosa26 locus. We observed multifocal sites of epithelial hyperplasia in 
the OSE of AdCRE injected (Gt)Rosa26Pik3ca*H1047R mice, but no tumor formation (Table 
1). Intrabursal AdCRE induction of PIK3CAH1047R, under the control of the endogenous 
promoter, also led to OSE hyperplasia in the mouse36, suggesting that constitutive 
overexpression of PIK3CAH1047R from the Rosa26 locus does not further augment this 
process.
We next evaluated the combinatorial effects of ARID1A loss and PIK3CA activation by 
performing AdCRE injections into the ovarian bursa of Arid1afl/fl;(Gt)Rosa26Pik3ca*H1047R 
mice. In stark contrast to the single mutants, Arid1afl/fl;(Gt)Rosa26Pik3ca*H1047R mice 
rapidly developed primary ovarian tumors and showed evidence of abdominal distension, 
warranting sacrifice with a median latency period of 7.5 weeks post-AdCRE injection (Fig. 
2J–M). Evidence for tumor-specific ARID1A loss and PIK3CAH1047R expression or PI3K 
pathway activation was detected by PCR amplification of tumor cDNA or by tumor 
immunohistochemistry (IHC) for ARID1A and phosphorylation of AKT at serine 473 (P-
AKT S473) (Fig. 2B–I). Increased morbidity coincided with the presentation of hemorrhagic 
ascites (Fig. 2J,L). Peritoneal metastases were detected in approximately 50% of the double 
mutants, often residing near the contralateral, uninjected ovary (Fig. 2K, see Table 1). 
Distant metastases beyond the abdominal cavity were not evident upon gross examination. 
We did not find evidence for genome instability in Arid1afl/fl;(Gt)Rosa26Pik3ca*H1047R 
tumor samples using mouse high-density SNP arrays (Supplementary Fig. 2).
ARID1A haploinsufficiency does not lead to tumor formation
Several studies point to a gene dose-dependent role for ARID1A in tumor suppression given 
the high incidence of heterozygous tumor mutations in cancer19. To determine if an 
ARID1A haploinsufficiency coupled with PI3K pathway activation leads to ovarian cancer 
in our model, we performed AdCRE injections on Arid1afl/+;(Gt)Rosa26Pik3ca*H1047R 
mice. OSE hyperplasia was observed in 5 of 7 Arid1afl/+;(Gt)Rosa26Pik3ca*H1047R mice, 
but evidence of tumor formation was not detected after the 11-week observation period, 
similar to the (Gt)Rosa26Pik3ca*H1047R only cohort (Fig. 2N,O, see Table 1). These data are 
consistent with the observation that most OCCC tumors carrying heterozygous mutations in 
ARID1A show loss of ARID1A immunoreactivity and support the notion that additional 
mechanisms lead to loss of ARID1A protein expression in OCCC18, 37. Thus, ARID1A 
likely follows the classical “two-hit” model of tumor suppression in OCCC.
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Therapeutic PIK3CA inhibition prolongs animal survival
We next sought to examine the role of continued PIK3CA activation in the progression of 
ARID1A-deficient ovarian tumors and determine whether therapeutic PIK3CA inhibition 
would inhibit tumor cell growth and improve animal survival. Primary EOC tumor cells 
were isolated from the exfoliated tumor cell aggregates present in ascites fluid of tumor-
burdened Arid1afl/fl;(Gt)Rosa26Pik3ca*H1047R mice and subcultured using established 
methods (Fig. 3A). Isolated tumor cells displayed ARID1A loss and heightened PI3K 
signaling, as evidence by loss of ARID1A immunoreactivity and increased P-AKT S473 
levels compared to normal OSE cells (Fig. 3B). Administration of the pan-class I PI3K 
inhibitor, BKM120 (Buparlisib) led to a dose-dependent decrease in P-AKT S473 and 
concomitant reduction in tumor cell viability (IC50= 0.96 +/− 0.25 µM) (Fig. 3C,D). We 
next administered chow-fed BKM120 to Arid1afl/fl;(Gt)Rosa26Pik3ca*H1047R mice for 3 
weeks, starting at week 4 post-AdCRE injection. The effectiveness of BKM120-dependent 
inhibition of PI3K signaling in chow-fed mice was accessed by tumor IHC for 
phosphorylation of the S6 Ribosomal Protein at serine 235/236 (P-S6) (Fig. 3E). BKM120 
treatment led to reduced P-S6 levels and extended the median latency period by 3.5 weeks 
(Fig. 3E,F). These data indicate that therapeutic PI3K inhibition promotes animal survival 
by inhibiting tumor cell growth, thus providing strong rationale for the use of PI3K 
inhibitors in OCCC treatment.
Mouse ovarian tumors manifest OCCC-like histopathology
Cardinal histopathological features of human OCCC include cells with clear cytoplasm, 
stromal hyalinization, solid, papillary, or tubulocystic tumor architectural patterns, and 
HNF1β immunoreactivity38. The ovarian tumors observed in Arid1afl/fl;
(Gt)Rosa26Pik3ca*H1047R mice were predominately solid in appearance with some papillary 
areas (Fig. 4A–D, see Table 1). Tubulocystic patterns were rarely observed (Fig. 4E, see 
Table 1). Neoplastic cells with clear cytoplasm, prominent nucleoli, and pleomorphic nuclei 
were observed in the tumors (see high magnification in Fig. 4A’-C’). Elongated spindle-
shaped cells with finely vacuolated cytoplasm were observed embedded in hyalinized 
matrix. Solid clear-cell carcinomas were observed directly attached to the ovarian surface 
(Fig. 4A). We rarely observed tumor cells organized into bands of glandular epithelium with 
distinct borders, and, in general, the tumors appeared poorly differentiated and highly 
disorganized. Primary tumor masses ranged from approximately 100 mg to over 1 g (Fig. 
4J). Differences in tumor size, metastatic potential, or morbidity did not correlate with any 
particular histologic feature.
In human OCCC, neoplastic cells that line luminal spaces often assume a ‘hobnail’ 
appearance, which crudely resembles a nucleus standing on the tip of a cytoplasmic stalk. 
Hobnail cells were often observed on the tumor periphery in regions where tumor cell 
exfoliation into luminal regions was occurring (Fig. 4D, I, K). Exfoliated, metastatic tumor 
cell aggregates often consisted of hobnail-shaped cells organized around either clear-cell or 
hyalinized cores (Fig. 4I). OSE hyperplasia and small clumps of hobnail cells were evident 
on the ovarian surface as early as one week following AdCRE injection, with exfoliated 
tumor cell aggregates and clear-cell-like features apparent at 2 weeks (Supplementary Fig. 
3). The tumors were also positive for the human OCCC marker, HNF1β, by IHC (Fig. 5B). 
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Thus, mouse ovarian tumors harboring coexistent ARID1A-PIK3CA mutations share 
histopathological features with human OCCC.
Tumor gene expression supports a role for IL-6 in OCCC
To further evaluate the relevance of our Arid1afl/fl;(Gt)Rosa26Pik3ca*H1047R ovarian tumor 
model to human OCCC, we performed a series of cross-species gene expression 
comparisons using a well-characterized gene expression dataset containing all four human 
EOC subtypes39. Gene expression profiles of mouse primary tumor samples and matched 
normal (uninjected) ovaries were generated by microarray. Consistent with our genetic 
model, ARID1A and PIK3CA expression levels were inversely correlated in comparisons 
between tumor and normal ovary samples, with PIK3CA upregulation strongly correlated 
with ARID1A downregulation in the tumor samples (Supplementary Fig. 4). We verified 
our microarray gene expression results by RT-PCR validation of KRAS, TFPI2, CDKN2A 
(P16), CDKN1A (P21), MUC16 (CA125), and VCAN expression (Supplementary Fig. 5). 
We next identified all coordinately regulated genes in both mouse tumors and human 
OCCC, as compared to species-matched normal ovaries. In comparisons of both mouse and 
human datasets, the control ovary samples showed high levels of gene expression variation, 
suggesting tissue sampling differences or general interspecies-specific gene expression 
differences (Supplementary Fig. 6). Focusing on those genes that remained unchanged in 
normal mouse and human ovaries, we identified 584 coordinately regulated genes (272 
upregulated; 312 downregulated) in mouse and human tumors (Supplementary Fig. 7). 
Mouse and human tumor gene expression patterns were enriched for genes involved in 
Interleukin-6 (IL-6) signaling, immune system function, focal adhesion, and regulation of 
the actin cytoskeleton, as compared to normal ovaries (Supplementary Figs. 6 and 7).
Since many of the upregulated genes we identified in cross-species comparisons with 
normal ovaries are likely to be found in other EOC subtypes (e.g. CA125) or generally 
found across most cancers, we next sought to identify an OCCC-specific gene signature for 
use in subtype-specific gene expression comparisons with the mouse tumors. To do this, we 
compiled a more refined ‘discriminant’ gene list for each subtype (e.g. clear-cell vs. all other 
EOC subtypes). We then compared the normalized raw expression values for each 
discriminant gene across all of the mouse tumor and human EOC samples. Using this 
analysis, we found that the gene expression patterns for mouse tumor and human OCCC 
samples were not statistically different (pval=0.6), suggesting that the OCCC-specific gene 
expression patterns are conserved between the two species (Fig. 5C). Several well-known 
markers of OCCC were identified as being highly expressed in the mouse tumors, including 
IL-6, STAT3, VCAN, and HIF1α, further supporting a role for heightened IL-6 signaling in 
OCCC tumor pathogenesis40, 41, 42 (Fig. 6A).
To further assess similarities between our genetic model and human OCCC, we compared 
the mouse tumor-specific gene expression profiles for our Arid1afl/fl;
(Gt)Rosa26Pik3ca*H1047R mouse model to those recently reported for the Arid1afl/fl; Ptenfl/fl 
mouse model by Guan et al.26, which is genetically similar endometrioid EOC. Both models 
relied on the intrabursal AdCRE injection method for mutation induction. We applied 
principal component analysis using the normalized expression values for all genes in the 
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tumor datasets for each mouse model. We found that each tumor sample clustered based on 
genotype or mutational pattern of the respective genetic model, with the exception of one 
Arid1afl/fl; Ptenfl/fl tumor (Supplementary Fig. 8). These findings are consistent with the 
marked phenotypic differences observed in our Arid1afl/fl;(Gt)Rosa26Pik3ca*H1047R tumors 
when compared to the phenotypes reported for Arid1afl/fl; Ptenfl/fl tumors by Guan et al.26.
Autocrine IL-6 signaling promotes tumor cell growth
IL-6 is an inflammatory cytokine that triggers JAK/STAT3 signaling and has prominent 
roles in tumor cell growth and differentiation43, 44. High levels of circulating IL-6 in cancer 
patients are associated with a poor prognosis43, 44. In addition to its increased expression in 
OCCC tumors, IL-6 has been detected in patient serum and tumor-derived cell lines, which 
has led to its proposed use as a therapeutic target in OCCC40, 41, 42. In support of our cross-
species microarray comparisons, we verified IL-6 expression in primary tumors and 
peritoneal metastases of Arid1afl/fl;(Gt)Rosa26Pik3ca*H1047R mice by RT-PCR (Fig. 6B). 
We also observed high levels of secreted IL-6 in the body fluids of tumor-burdened mice, 
with greater than 2000 pg/mL of IL-6 in ascitic fluid aspirates (Fig. 6C,D). Consistent with 
this, strong IL-6 immunoreactivity was also observed in the mouse tumors by IHC (Fig. 6E).
To understand the role of IL-6 in OCCC pathogenesis, we treated primary Arid1afl/fl;
(Gt)Rosa26Pik3ca*H1047R mouse ascites-derived tumor cells, isolated as described above, 
with anti-IL-6 neutralizing antibodies. Anti-IL-6 treatment reduced tumor cell viability and 
downregulated phosphorylation of STAT3 at tyrosine 705 (P-STAT3 Y705), suggesting that 
autocrine IL-6-STAT3 signaling promotes tumor cell growth (Fig. 6F,G). Next, we 
generated primary mouse tumor cell lines that stably express IL-6 short-hairpin RNAs 
(shRNA) for use in tumor growth assays (Fig. 6H,I). IL-6 shRNA-expressing cells showed 
reduced growth rates in culture, and media supplementation with recombinant IL-6 restored 
the normal growth patterns of IL-6 shRNA-expressing cells (Fig 6J). To further examine 
tumor cell autonomous roles for IL-6 in ovarian tumor cell growth, we grafted control 
shRNA- and IL-6 shRNA-expressing mouse tumor cells onto the flanks of immunodeficient 
nude mice. Remarkably, the ascitic tumor cell grafts were indistinguishable from the ovarian 
tumors with regards to histopathological features (e.g clear cytoplasm), despite being 
maintained in tissue culture and further grown under the skin of immunodeficient mice (Fig. 
6K,L). The rate of tumorgraft growth for IL-6 shRNA-expressing cells was significantly less 
than control shRNA-expressing cells, further indicating that autocrine IL-6 signaling 
contributes to OCCC pathogenesis by promoting tumor cell growth (Fig. 6M).
IL-6 induction requires coexistent ARID1A-PIK3CA mutations
To determine if coexistent ARID1A-PIK3CA mutations are required for IL-6 induction, we 
utilized an AdCRE-inducible primary OSE cell culture model. IL-6 expression was 
measured following AdCRE-infection of primary OSE cells isolated from mice carrying all 
mutant allele combinations. Loss of ARID1A or PIK3CA activation alone led to significant 
increases in IL-6 expression by RT-PCR and ELISA, and IL-6 induction was further 
enhanced when ARID1A and PIK3CA were co-mutated together in Arid1afl/fl;
(Gt)Rosa26Pik3ca*H1047R cells (Fig. 7A,B). Consistent with this, P-STAT3 Y705 levels 
also correlated with similar increases in IL-6 activity in AdCRE treated OSE cells (Fig. 7C). 
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ARID1A loss in AdCRE-treated Arid1afl/fl or Arid1afl/fl;(Gt)Rosa26Pik3ca*H1047R OSE 
cells did not further enhance PI3K pathway activity (Fig. 7C). We found that Arid1afl/fl;
(Gt)Rosa26Pik3ca*H1047R OSE cell proliferation was suppressed by treatment with anti-IL-6 
neutralizing antibodies following mutation induction with AdCRE, and that recombiant IL-6 
enhances normal OSE cell proliferation and IL-6-STAT3 signaling, further suggesting that 
IL-6 is both necessary and sufficient for tumor cell growth (Fig 7D–F). To determine if 
ARID1A is bound at the IL6 promoter under repressed conditions, we performed a series of 
ARID1A chromatin immunoprecipitation experiments in primary OSE cells. We used 
Arid1afl/fl;(Gt)Rosa26Pik3ca*H1047R OSE cells for these experiments so that AdCRE-treated 
or ARID1A-depleted cells could be used as a control for ARID1A immunoprecipitation 
specificity. In AdControl-treated cells, increased ARID1A occupancy was observed at sites 
near the IL6 promoter, but not at distal upstream or downstream sites (Fig. 7G). ARID1A 
occupancy at this site decreased in manner consistent with ARID1A depletion following 
AdCRE infection. These data indicate that coexistent ARID1A-PIK3CA mutations lead to 
IL-6 upregulation.
Discussion
Our data support a genetic epistasis model wherein ARID1A and PIK3CA mutations 
cooperate and ovarian cancer can arise only when these genes are co-mutated in the mouse 
OSE. The short latency period, lack of copy number variation, and OCCC-like histological 
and molecular features we observed are also consistent with coexistent ARID1A-PIK3CA 
mutations being a major driver of OCCC in humans. Our results suggest that high levels of 
tumor cell-derived IL-6 are promoting tumor growth in OCCC. Indeed, the top pathway we 
identified in common between species is comprised of genes involved in this pathway, 
suggesting that IL-6-STAT3 signaling is inherent to OCCC biology. Hence, IL-6 serves as 
both a molecular marker and a prospective therapeutic target in OCCC. Therefore, anti-IL-6 
antibody (Siltuximab) therapy may prove to be a safe and effective treatment strategy for 
OCCC patients. More broadly, our findings further demonstrate that the continued 
identification of tumor mutations (i.e. TCGA projects) will allow us to identify potential 
functional relationships among recurrent mutational patterns or cancer pathways that would 
have otherwise gone unnoticed.
The OSE-derived tumor phenotypes we observed in our Arid1afl/fl;
(Gt)Rosa26Pik3ca*H1047R mouse model of OCCC greatly contrasted with those reported by 
Guan et al.26 for Arid1afl/fl; Ptenfl/fl mice. For example, all of the tumor-burdened Arid1afl/fl;
(Gt)Rosa26Pik3ca*H1047R mice were morbid or succumbed to death within 3 months after 
AdCRE injection, whereas Guan et al.26 reported tumors in a subset of Arid1afl/fl; Ptenfl/fl 
mice after 6 months, indicating stark differences in tumor latency or survival. Molecular 
differences were evident in tumor gene expression comparisons between the two mouse 
models, as each gene expression dataset parsed the majority of tumor samples based on its 
respective mutational pattern or genotype. These data point to potential functional 
differences between ARID1A-PIK3CA and ARID1A-PTEN mutational patterns in Type I 
EOCs and support the idea of a possible PI3K-AKT-mTOR-independent role for PTEN in 
endometrioid EOC26. Alternatively, it remains possible that clear-cell tumorigenesis is 
driven, in part, by an alternative AKT-independent mechanism downstream of oncogenic 
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PIK3CA mutations45, 46. Additional pharmacological studies targeting downstream effectors 
or alternative signaling pathway components will further address potential PI3K pathway-
independent mechanisms of endometrioid versus clear-cell tumorigenesis.
Several theories on the origins of OCCC have been proposed. Our data strongly suggests 
that the OSE harbors a cancer-prone cell population that gives rise to OCCC-like tumors in 
the mouse, which is consistent with the classical view of EOC pathogenesis. Nonetheless, 
our mouse model does not address the role of distal endometriotic explants or other putative 
precursor lesions in OCCC pathogenesis. Specifically targeting the ARID1A-PIK3CA 
mutational pattern to other tumor-prone epithelia within the Müllerian duct system would 
add relevance to our findings and help to further clarify the origins of EOC. An improved set 
of inducible CRE alleles would facilitate these experiments.
Inflammation of coelomic epithelial cell-derivatives in the female reproductive tract is 
thought to be a major contributor to malignant transformation in endometriosis-associated 
EOC, like OCCC5, 47. Accordingly, inflammatory mediators, aberrant immune modulation, 
or irregular reproductive hormone levels are thought to play a major role in malignant 
transformation5, 47. Inflammatory cytokine signaling pathways, like IL-6, may be part of the 
natural inflammatory repair process accompanying each ovarian and menstrual cycle that, 
when left unchecked, promotes unregulated epithelial cell growth. In support of this, our 
data demonstrate that OSE cells are competent to respond to and upregulate IL-6. Therefore, 
the incomplete resolution of epithelial cell inflammation during these repair processes may 
represent a common mechanism underlying OCCC tumorigenesis, irrespective of mutational 
pattern.
The identification of IL-6 as a physiological target of ARID1A tumor suppressor activity in 
our OCCC tumor model raises many important questions regarding the role of ARID1A-
containing SWI/SNF complexes in normal coelomic epithelial cell homeostasis. Indeed, 
ARID1A mutations have been identified in a wide variety of cancers originating from 
coelomic epithelial-derivatives throughout the gynecologic tract. Moreover, loss of ARID1A 
immunoreactivity is observed in endometriosis, a disease intimately associated with 
inflammation48, 49, 50. Endometriosis is also characterized by increased IL-6 expression, but 
the relationship between ARID1A loss and IL-6 upregulation in endometrial tissue is 
unknown51, 52. Thus, ARID1A may regulate coelomic epithelial cell homeostasis and 
prevent tumorigenic conversion by negatively regulating the inflammatory programs 
required for normal tissue repair during the female reproductive cycle. It will be interesting 
to know if reproductive hormones influence ARID1A activity in this regard. Additional 
work on the propensity of ARID1A mutant epithelial cells to undergo malignant 
transformation in response to inflammatory “insults” or the role of key inflammatory 
response pathways in this process will be required to address these hypotheses. Thus, loss of 
ARID1A-containing SWI/SNF complexes might expose the “darker,” pro-tumorigenic side 
of inflammation.
How do oncogenic PI3K signaling mutations contribute to this process or lead to increased 
IL-6 expression? Positive regulators of IL-6 include JAK/STAT, PI3K, EGFR/HER2, 
RAS/RAF/MEK, TNF/TLR/IL1 or RAS/ERK oncogenic pathways and AP-1, SP1, NF-κB, 
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C/EBP, STAT3, and CREB transcription factors53. IL-6-mediated JAK/STAT activation can 
further promote IL-6 transcription53. We propose that oncogenic PIK3CAH1047R mutations 
act like inflammatory “insults” and drive the signaling loop that sustains high levels of IL-6 
production in the absence of negative regulation by ARID1A (Fig 7H). Additional studies 
focusing on the intricacies of this feed-forward signaling loop and the potential crosstalk 
mechanisms occurring among the various pathways that sustain it will further explain why 
coexistent ARID1A-PIK3CA mutations are found in a wide variety of human cancers.
Material and Methods
Generation of the Arid1a conditional mouse allele
The Arid1afl conditional mutant mouse allele was engineered using the Bacterial Artificial 
Chromosome (BAC) recombineering methods developed by Liu et al54. Correctly targeted 
mouse ES cell clones were identified by Southern blotting. The Neo selection cassette used 
for targeting was removed by FLP-mediated recombination54. Targeted ES cells were 
injected into C57Bl6 blastocysts and implanted into pseudopregnant females. Germline 
animals were detected by coat color and PCR confirmation of tail DNA samples.
AdCRE-mediated genetic recombination in the ovary
To induce genetic recombination in the ovarian surface epithelium (OSE), we employed a 
modified version of the ex-vivo Adenovirus-CRE (AdCRE) intrabursal delivery method7, 29. 
Briefly, AdCRE particles (obtained from the University of Iowa Gene Transfer Core) were 
diluted in sterile 1X Dulbeccos’s phosphate buffered saline (dPBS) containing 8 µg/mL 
polybrene. Deeply anesthetized 8–10 week old mice were given a single 5 µL injection of 
AdCRE particles (2.5×107 plaque-forming units or pfu) into the right ovarian bursal cavity 
of the surgically exposed ovary using a sterile 31-gauge needle. Immediately following 
AdCRE injection, the surgically excised ovaries were washed with sterile 1X dPBS and 
placed back into the abdominal cavity. The surgeries were performed on multiple occasions. 
Age- and genotype-matched, non-littermate animals were randomized prior to AdCRE 
injection. The surgeon was blinded to the genotypes prior to surgery and AdCRE injection. 
All surgical procedures were performed in accordance with protocols approved by the 
University of North Carolina at Chapel Hill Institutional Animal Care and Use Committee.
Mouse husbandry and genotyping
All mice were maintained on an outbred (random) genetic background using CD-1 mice 
(Charles River). (Gt)ROSA26Pik3ca*H1047R and Sox2CRE alleles were purchased from The 
Jackson Laboratory and identified by PCR using published methods28, 35. Arid1a+/+; 
Arid1afl/+; Arid1afl/fl alleles were distinguished by PCR using the following primer set: (F) 
CTAGGTGGAAGGTAGCTGACTGA; (R) TACACGGAGTCAGGCTGAGC. Combining 
the forward primer (from above) with the following reverse primer amplifies the CRE-
excised allele: (R) AGAGTAACTAATAACTGCTGGAGGATG. PCR products were 
resolved by 2%–Tris-Borate-EDTA agarose gel electrophoresis. Endpoints were palpable 
tumors (>1.5 cm3), visible hemorrhagic ascites or severe abdominal distension, and signs of 
severe illness, such as dehydration, hunching, ruffled fur, signs of infection, or non-
responsiveness. Sample sizes within each genotype were chosen based on the proportions of 
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animals with tumors and/or survival between each experimental group or a Kaplan-Meyer 
log rank test for survival differences. Wholemount live animal luminescent imaging was 
performed using the IVIS Optical System and reagents (Perkin Elmer) according to the 
manufacturer’s instructions. Wholemount images of mice or necropsies were aquired using a 
Canon PowerShot SD1100 IS digital camera and a tabletop tripod. Wholemount tumor 
specimens were imaged on a Leica MZ FLIII stereomicroscope using a DS Ri1 digital 
camera (Nikon). All mice were maintained at the University of North Carolina at Chapel 
Hill, Animal Facility using standard techniques in accordance with protocols approved by 
the University of North Carolina at Chapel Hill Institutional Animal Care and Use 
Committee.
In vivo drug treatments
The pan-PI3K inhibitor, BKM120 (Novartis) was milled by Research Diets using a vehicle- 
or carrier-free formulation similar to standard husbandry diets and dosed at 40 mg kg−1 
based on the average daily oral consumption of a mouse55, 56, 57. AdCRE-injected animals 
were randomized prior to drug treatment. Control or untreated mice were given a standard 
husbandry diet. All drug treatments were performed in accordance with protocols approved 
by the University of North Carolina at Chapel Hill Institutional Animal Care and Use 
Committee.
RT-PCR
Total RNA was extracted from pulverized tumor samples or ovarian epithelial cells using 
the TRIzol method (Invitrogen), followed by an RNA cleanup step and on-column DNA 
digestion using the RNAeasy mini prep kit (Qiagen) according to the manufacturers’ 
instructions. To analyze ARID1A and (Gt)Rosa26Pik3ca*H1047R gene transcript levels, real-
time quantitative PCR was performed using Ssofast PCR master mix (Biorad) and a CFX96 
thermocycler (Biorad) with the following gene-specific primers: ARID1A (F) 
CTGAAGGACAAAGGTGACT, ARID1A (R) CACAACTGCGAACTTCTC; R26exon1 
(F) CTAGGTAGGGGATCGGGACTCT, PIK3CAcDNA (R) 
AATTTCTCGATTGAGGATCTTTTCT35. The following gene specific primers were used 
to validate the microarray expression data: KRAS (F) 
AGAGGAGTACAGTGCAATGAGG, KRAS (R) AGGCACATCTTCAGAGTCCTTT; 
TFPI2 (F) AAGGGCTTGTGTGAACCACG, (R) CCACCACAGCCAGTATAGGTG; 
CDKN1A (F) ATCCAGACATTCAGAGCCACAG, (R) 
ACGAAGTCAAAGTTCCACCGT; CDKN2A (F) GCTTCTCACCTCGCTTGTCA, (R) 
AGTGACCAAGAACCTGCGAC; MUC16 (F) CTCATCTGCTTGGCGGTACT; (R) 
GAACCCTGCTAGGGAAGAGC; VCAN (F) GAAGGGAACAGTTGCTTGCG, (R) 
TTAGGCATTGCCCATCTCCC; IL-6 (F) CACTTCACAAGTCGGAGGCT, (R) 
CTGCAAGTGCATCATCGTTGT. Expression was calculated from three independent 
experiments using ΔΔCt methods. Expression levels were normalized to βACTIN. Statistical 
differences were detected using a two-tailed Student’s t test. The following H1047 spanning 
PCR primer pair was used to distinguish endogenous PIK3CA from Rosa26-derived, 
PIK3CAH1047R gene transcripts: (F) TTCAATGATGCTTGGCTCTG; (R) 
CTGCTTGATGGTGTGGAAGA. The PCR products were digested with MslI and resolved 
by 2%–Tris-Borate-EDTA agarose gel electrophoresis.
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Western blots were performed using the following antibody dilutions and standard 
chemiluminescent detection methods or Li-COR Bioscience Odyssey fluorescent western 
blotting reagents: 1:1,000 ARID1A (A301-041A, Bethyl Labs,), 1:500 IL-6 (ab6672, 
Abcam), 1:1000 Phospho-AKT Ser473 (4060, Cell Signaling), 1:1000 AKT (4691, Cell 
Signaling), 1:100 STAT3 (sc-482, Santa Cruz Biotechnology), 1:1000 Phospho-STAT3 
Tyr705 (9145, Cell Signaling), and 1:5,000 βACTIN (Abcam). Membranes were blocked in 
1X PBS supplemented with 5% (w/v) non-fat dry milk (Blotto A) or 1X Tris-buffered saline 
(TBS) [pH 7.6] supplemented with 5% (w/v) bovine serum albumin (BSA). Primary 
antibody incubations were performed in 1X PBS supplemented with 1% (w/v) non-fat dry 
milk, 1% (w/v) BSA, and 0.05% (v/v) Tween-20 (Blotto B) or 1X TBS [pH 7.6] 
supplemented with 5% (w/v) BSA. Western blot images have been cropped for presentation. 
Full size western blot images with antibody dilutions and blocking buffer conditions are 
presented in Supplementary Figures 9 and 10.
ELISA
IL-6 ELISAs were performed using the OptEIA mouse IL-6 kit reagents (BD Bioscience) 
according to the manufacturer’s instructions. ELISA measurements were normalized to total 
cellular protein.
Copy number and TCGA computational analyses
Tumor and matched control DNA samples were processed for hybridization on the high 
density Mouse Universal Genotyping SNP Array (MegaMUGA, Neogen) using published 
methods58. Copy number analysis was performed using ASCAT59. ARID1A and/or 
PIK3CA TCGA mutation frequency was identified by querying the cBioPortal on 2014-10–
21 using the R API 60, 61.
Microarray and cross-species gene expression comparisons
Total RNA was isolated from 9 primary tumor specimens and 9 matched normal 
(uninjected) ovaries as described above. Total RNA (250 ng) was used to synthesize 
fragmented and labeled sense-strand cDNA and hybridize onto Affymetrix Mouse Gene 2.1 
ST peg plate arrays. The mouse data were uploaded to the Gene Expression Omnibus (GEO) 
under the accession number: GSE57380. Affymetrix CEL files were normalized using the 
Robust Multichip Average normalization method62. Expression changes (tumor versus 
control ovary) were determined using Linear Models for Microarray Data Analysis 
(LIMMA)63 or Significance Analysis of Microarray (SAM) analysis64. Probes with a false 
discovery rate (FDR) of 0% were considered statistically significant. For mouse-human 
cross species comparisons, expression data for human OCCC and normal ovaries were 
downloaded from GEO under the accession number GSE600839. Heat maps and 
dendrograms were generated with Java TreeView or R (www.R-project.org). Histological 
sub-type specific gene signatures were derived by first identifying differentially expressed 
genes between human normal tissue and cancer tissue in GSE6008. Next, differentially 
expressed genes were identified comparing each histological subtype to all other histological 
subtypes. We considered only upregulated genes, and any genes that were upregulated in 
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both the tumor versus normal comparison and in a particular subtype were removed because 
these are not specific to a histological subtype and may reflect generic pan-cancer gene 
expression patterns. To compare human and mouse samples from these gene sets we first 
determined Z-scores for each gene within mouse or human. We combined these Z-scores 
and Z-scored the combined data using all human and mouse tumor samples in GSE6008 and 
this study. Pathways analysis was perfomed using the GSEA Molecular Signatures Database 
(MSigDB)65, 66 or Ingenuity Pathway Analysis (IPA) (Qiagen).
Ascites-derived tumor cell and OSE cell culture
Primary ascites-derived ovarian tumor cells were isolated and grown as previously 
described67. To facilitate complete red blood cell lysis, the cell isolates were incubated and 
washed in deionized H2O prior to re-suspension in growth medium. Mouse OSE cells were 
isolated and cultured as previously described68. To induce CRE-mediated recombination in 
OSE cells, the cells were infected with AdCRE or AdControl particles (obtained from the 
University of Iowa Gene Transfer Core) at an MOI of 200 for 2 hours in serum-free media. 
Infected OSE cells were then placed in normal growth medium and allowed to recover for 3 
days prior to further manipulation. BKM120 (Chemitek), low endotoxin rat anti-mouse IL-6 
neutralization antibody (R&D systems, MAB406), non-specific rat IgG1 isotype control 
antibody (R&D systems, MAB005), or recombinant mouse IL-6 protein (R&D systems, 
406-ML-005) were reconstituted according to the manufacturers’ instructions and used as 
described in the text. For all antibody neutralization experiments, the cells were re-fed daily 
with the appropriate concentrations of antibody. Primary ascites-derived ovarian tumor cells 
were stably transduced with Mission pLKO.1-puro IL-6 shRNA (Hairpin sequence: 
CCGGCCAGAGTCCTTCAGAGAGATACTCGAGTATCTCTCTGAAGGACTCTGGTT
TTTG) (Sigma, TRCN0000067551) or non-target control shRNA (Sigma, SHC016V) 
Lentiviral transduction particles according to the manufacturers’ instructions. The MTT 
assay kit (Roche) was used to measure cell viability. Ascites-derived tumor cells and OSE 
cells were passaged using Accutase (Invitrogen). Half-maximal inhibitory concentrations 
(IC50) were calculated by curve-fitting using Kaleidagraph software (Synergy).
Tumor grafts
Primary ascites-derived ovarian tumor cells expressing control- or IL-6 shRNAs were 
harvested by Accutase digestion and washed in 1X Dulbecco’s phosphate buffered saline. 
The cells were then injected subcutaneously into the right flanks of immunodeficient mice at 
a concentration of 5×10e7 cells/mL in a 1:1 (v/v) solution of 1X Dulbecco’s phosphate 
buffered saline and Cultrex basement membrane extract (3432-005-01, Trevigen). Tumor 
graft volumes were calculated using bi-weekly caliper-based measurements and growth rates 
were based on these volumetric measurements. All tumor grafts were performed in 
accordance with protocols approved by the University of North Carolina at Chapel Hill 
Institutional Animal Care and Use Committee.
Histology and immunohistochemistry
For indirect immunohistochemistry of slides, 10% neutral buffered formalin-fixed paraffin 
sections were processed for heat-based antigen unmasking in 10 mM sodium citrate [pH 
6.0]. Sections were incubated with the following antibody dilutions: 1:50 ARID1A (Clone 
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PSG3, sc-32761, Santa Cruz Biotechnology), 1:100 Cytokeratin 8 (TROMAI, DSHB), 1:50 
phospho-AKT Ser473 (4060, Cell Signaling), 1:50 phospho-S6 Ribosomal Protein 
Ser235/236 (4858, Cell Signaling), 1:100 HNF1β (sc-7411, Santa Cruz Biotechnology), or 
1:400 IL-6 (ab6672, Abcam). Vectastain Mouse-on-Mouse blocking reagents (Vector Labs) 
were used for ARID1A immunohistochemistry. SignalStain antibody diluent (8112, Cell 
Signaling) and SignalSlide AKT controls (8115, Cell Signaling) were used for phospho-
AKT Ser473 and phospho-S6 Ribosomal Protein Ser235/236 immunohistochemistry. 
Secondary detection was performed using Vectastain ABC System reagents (Vector Labs). 
Sections processed for immunohistochemistry were lightly counter-stained with 
Hematoxylin QS or Methyl Green (Vector Labs). Routine Hematoxylin and Eosin (H&E) 
staining of sections was perfomed by University of North Carolina, Lineberger Cancer 
Center, Animal Histopathology Core. Histological tumor assessments were reviewed by a 
UNC animal pathologist. Histological sections were analyzed and photographed on an 
Olympus BX51 microscope using bright-field optics and a DP series digital camera 
(Olympus).
Chromatin immunoprecipitation
Primary OSE cells were fixed in growth media containing 1% methanol-free formaldehyde 
(Pierce) for 10 min. at room temperature. The cells were washed twice with 1X dPBS and 
then swelled in cell lysis buffer (5 mM Tris-Cl [pH 8.0]; 85 mM KCl; 1% IGEPAL CA-630) 
for 10 min. on ice. Swollen cells were homogenized (20 strokes) with a B-type dounce 
homogenizer on ice to facilitate nuclei release. Isolated nuclei corresponding to 1×10e7 cell 
equivalents per 500 µL of nuclear lysis buffer (50 mM Tris-Cl [pH 8.0], 10 mM EDTA, and 
0.3% SDS) and then sonicated using a water bath-cooled Diagenode Biorupter sonicator and 
1.5 mL TPX microtubes (200 µL sample volume per tube) to an average DNA length 
between 300 and 700 bp. Chromatin concentrations were determined using a BCA protein 
assay kit (Pierce). Chromatin samples were diluted to 300 µg per 200 µL of nuclear lysis 
buffer and then cleared by centrifugation at 10,000Xg. Pre-cleared chromatin samples (200 
µL each) were added to 800 µL (1:5 dilution) of ChIP dilution buffer (50 mM Tris-Cl [pH 
7.5]; 150 mM NaCl; 5 mM EDTA; 0.5% IGEPAL CA-630; 1% TX-100) and incubated with 
10 µg of prebound ARID1A (Clone PSG3, 04-080, Millipore) Protein G dynal beads 
(Invitrogen) overnight at 4°C. The Protein G dynal bead-anti-ARID1A immune conjugates 
were washed twice with 1 mL ChIP dilution buffer, 3-times with 1 mL ChIP dilution buffer 
supplemented with 500 mM NaCl, twice with 1 mL ChIP dilution buffer, followed by a final 
wash in 1 mL low salt TE buffer (10 mM Tris-Cl [pH 8.0]; 1 mM EDTA; 50 mM NaCl). 
The immunoprecipitated samples were eluted in 100 µL of elution buffer (50 mM NaHCO3; 
1% SDS) at 62°C for 20 min. using an Eppendorf tube mixer. The crosslinks were reversed 
by adding NaCl to a final concentration of 0.2M followed by an overnight incubation at 
65°C. The samples were then deproteinated with Proteinase K and purified using the ChIP 
DNA Clean & Concentrator kit (Zymo Research) according to the manufacturer’s 
instructions. Real-time quantitative PCR using Ssofast PCR master mix (Biorad) and a 
CFX96 thermocycler (Biorad) was performed using the following gene-specific primer 
pairs: (IL-6, Site A) GCAACTCTCACAGAGACTAAAGG, 
GGACAACAGACAGTAATGTTGC69; (IL-6, Site B) 
CTAGCCTCAAGGATGACTTAAGC, CTATCGTTCTTGGTGGGCTCCAGAGC70; 
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(IL-6, Site C) GCCTTCTTGGGACTGATGCT, GACAGGTCTGTTGGGAGTGG. Data 
from three independent primary OSE cell isolations were averaged and plotted as a 
percentage of the total input.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. A new Arid1a conditional allele to explore ARID1A tumor suppressor function in vivo
(A) Targeting scheme to insert two loxP sites flanking exon 5 and 6 of mouse ARID1A. (B) 
Representative Southern blot showing properly targeted ES cell clones. Insertion of loxP 
sites generates 5.6 kb EcoRV and 8.5 kb ApaI genomic fragments. (C) PCR genotyping and 
quantitative, dual-color fluorescent western blot of ARID1A (red) and βACTIN (green) 
protein expression in whole-embryo lysates from four Arid1afl/+ and four 
Arid1afl/+;Sox2Cre0/+ embryos. (D) Graph of quantitative western blot results depicting 
normalized protein levels. Significant differences based on the average normalized protein 
expression ±SD of four independent embryos were calculated using a two-tailed Student’s t 
test (p-values <0.05 were considered significant). (E,F) Representative LacZ-stained, control 
(uninjected) or intrabursal AdCRE-injected (Gt)Rosa26lacZ ovary showing patterns of 
CRE-mediated recombination in the ovarian surface epithelium. (F, inset) Histological 
section of LacZ-stained AdCRE-injected (Gt)Rosa26lacZ ovary. (G-I) Live-luminescence 
overlaid whole-mount images of an intrabursal AdCRE injected, (Gt)Rosa26luciferase 
female mouse. (I) Excised reproductive tract. Asterisks in H indicate wound staple.
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Figure 2. Concurrent ARID1A loss and PIK3CA activation leads to ovarian tumorigenesis in the 
mouse
(A) Plot of ARID1A and PIK3CA alterations across available TCGA datasets. Mutation or 
co-mutation frequencies are expressed as a percentage of all tumor samples for each cancer. 
A Fisher’s exact test was used to calculate the significance of association between ARID1A 
and PIK3CA mutations (*p-value <0.05). (B) Genotyping scheme to detect CRE-deleted 
(Arid1aΔ) allele in tumor genomic DNA samples. RT-PCR was used to distinguish PIK3CA 
and transgenic (Gt)Rosa26Pik3ca*H1047R transcripts in tumor RNA samples. The H1047R 
mutation in (Gt)Rosa26Pik3ca*H1047R protects against MslI digest of amplified tumor 
cDNA. (C) ARID1A loss or (Gt)Rosa26Pik3ca*H1047R transcripts were detected in tumor 
RNA samples by RT-PCR. Significant differences based on the average normalized mRNA 
expression ±SD between replicates of a control liver sample and replicates of three 
independent tumor samples were calculated using a two-tailed Student’s t test (p-values 
<0.05 were considered significant). (D,E) ARID1A expression is observed in cells 
throughout the normal uterus and ovary by IHC. (E) ARID1A is expressed in the OSE of 
normal ovaries (arrowhead). (F) ARID1A expression is not observed in the tumors. (E) P-
AKT S473 levels are low in the normal uterus. (H, I) P-AKT S473 in the normal ovary is 
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highest in the OSE (E, arrowhead) and these levels are greatly increased in ovarian tumors 
(F, arrowhead). Asterisk in E denotes an oocyte. All sections processed for IHC were lightly 
counter-stained with methyl green. (J,K) Morbid Arid1afl/fl;(Gt)Rosa26Pik3ca*H1047R 
mouse at sacrifice with hemorrhagic ascites (inset), primary ovarian tumor of moderate size, 
and bilateral tumor metastases (arrowheads). (L,M) Morbid Arid1afl/fl;
(Gt)Rosa26Pik3ca*H1047R mouse at sacrifice with hemorrhagic ascites (inset), large primary 
ovarian tumor, and no visible metastases. The mice shown in J-M were sacrificed at 7 and 9 
weeks post-AdCRE, respectively, because of visible ascitic fluid burden. (N,O) Arid1afl/+;
(Gt)Rosa26Pik3ca*H1047R mice at 11-weeks post-AdCRE showing no evidence for tumor 
formation. In K and M, dashed circles indicate primary ovarian tumor on injected ovary. In 
N, arrows denote the AdCRE injected ovary. In K, M, and O, asterisks denote the uninjected, 
control ovary. UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; 
STAD, stomach adenocarcinoma; CESC, cervical squamous cell carcinoma and 
endocervical adenocarcinoma; HNSC, head and neck squamous cell carcinoma; COAD/ 
READ, colon and rectum adenocarcinoma; LUSC, lung squamous cell carcinoma; BRCA, 
breast invasive carcinoma; LUAD, lung adenocarcinoma; LGG, brain lower grade glioma; 
OV, ovarian serous cystadenocarcinoma; KIRC, kidney renal clear-cell carcinoma; LAML, 
acute myeloid leukemia; ACC, adrenocortical carcinoma; BLCA, bladder urothelial 
carcinoma; GBM, glioblastoma multiforme; KICH, kidney chromophobe; KIRP, kidney 
renal papillary cell carcinoma; PAAD, pancreatic adenocarcinoma; PRAD, prostate 
adenocarcinoma; SKCM, skin cutaneous melanoma; THCA, thyroid carcinoma.
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Figure 3. Therapeutic PIK3CA inhibition promotes animal survival by reducing tumor cell 
viability
(A) Primary ascites-derived tumor cell isolation scheme. (B) Representative western blots to 
highlight the primary tumor cell validation scheme and demonstrate that ARID1A loss and 
heightened P-AKT S473 is observed in primary Arid1afl/fl;(Gt)Rosa26Pik3ca*H1047R ascitic 
tumor cells versus normal ovarian surface epithelial (OSE) cells. (C) Western blots of P-
AKT S473 and total AKT levels in Arid1afl/fl;(Gt)Rosa26Pik3ca*H1047R ascitic tumor cells 
grown in the presence 10, 1, 0.001, or 0 µM BKM120 or equivalent dilutions (v/v) of 
DMSO vehicle control for 48 hrs. (D) BKM120 treatment reduces tumor cell viability with a 
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half-maximal inhibitory concentration (IC50) of 0.96 +/− 0.25 µM. Significant differences 
based on the average percent inhibition ±SD of three independent tumor cell lines treated 
with BKM120- versus vehicle-treated cells were calculated using a two-tailed Student’s t 
test (*p-value <0.05). (E,F) Administration of chow-fed BKM120 reduces PI3K pathway 
activity, as shown by reduced P-S6 Ser235/236 levels, and extends the Arid1afl/fl;
(Gt)Rosa26Pik3ca*H1047R median survival latency to 11 weeks. BKM120 treatment 
commenced 4 weeks after AdCRE injection. P-S6 Ser235/236 IHC was performed on tumor 
histological sections from three independent BKM120 treated or untreated mice. (F) 
Untreated Arid1afl/fl;(Gt)Rosa26Pik3ca*H1047R mice succumb to cancer with a median (µ1/2) 
latency of period of 7.5 weeks. Statistical differences in survival (BKM120 chow-fed versus 
untreated) were calculated using a log rank test (p-values <0.05 were considered 
significant).
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Figure 4. Arid1afl/fl;(Gt)Rosa26Pik3ca*H1047R ovarian tumors manifest clear-cell-like 
histological features
(A–E) Hematoxylin and Eosin (H&E) stained sections of tumor architectural patterns 
observed in intrabursal AdCRE-injected Arid1afl/fl;(Gt)Rosa26Pik3ca*H1047R mice. Whole-
mount tumor images are shown inset in A and E. Asterisks denote the uterus. Dotted line A’ 
demarcates the ovarian surface-tumor boundary. Arrowhead in D’ denotes a hobnail cell. 
(F–H) H&E stained sections of Arid1afl/fl;(Gt)Rosa26Pik3ca*H1047R tumor metastases found 
on the surface of gastrointestinal tract (F), kidney (G), and uninjected, control ovary (H). 
Panels A’-H’ are high magnification images of regions demarcated by dashed boxes in A-H. 
(I) H&E stained exfoliated tumor cell aggregate. (K) H&E stained example of hobnail cells 
on the luminal surface a tumor. Arrowheads in D’, F’, I, and K denote hobnail cells on 
tumor surface. (J) Dot plot of primary tumor mass compared to uninjected control ovary. 
Significant differences based on the average mass ±SD between tumors and matched 
uninjected ovaries were calculated using a two-tailed Student’s t test (p-values <0.05 were 
considered significant). (L–N) H&E stained high magnification images of the ovarian 
surface from Arid1afl/+;(Gt)Rosa26Pik3ca*H1047R, (Gt)Rosa26Pik3ca*H1047R, and Arid1aflfl 
mice. (M,N) OSE hyperplasia (arrowheads) is observed in (Gt)Rosa26Pik3ca*H1047R and 
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Arid1afl/+;(Gt)Rosa26Pik3ca*H1047R mice. OV, ovary; Oo, oocyte; T, tumor; IE, intestinal 
epithelium; KD, kidney; OV, ovary; UT, uterus.
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Figure 5. Arid1afl/fl;(Gt)Rosa26Pik3ca*H1047R ovarian tumors and human OCCC share 
molecular characteristics
(A) H&E stained image of Arid1afl/fl;(Gt)Rosa26Pik3ca*H1047R tumor histology. (B) Near-
adjacent histological section showing HNF1β immunoreactivity by IHC. (A’,B’) High 
magnification images of regions demarcated by dashed boxes in A and B. (C) Box plots of 
normalized expression values of human OCCC discriminant genes (N=159) for all mouse 
tumor and human EOC subtype samples. Significant differences between the mouse tumors 
and each human histological EOC subtype were calculated using a Wilcoxon test 
(*significant p-value of <0.05; #not significant p-value=0.6). NS, not significant.
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Figure 6. Tumor-derived IL-6 promotes OCCC tumor cell growth and survival
(A) Top OCCC-specific genes in common between mouse and human tumors. Top six IPA 
and MSigDB (GSEA) predictions of the top upregulated genes are included. (B) RT-PCR 
validation of IL-6 expression in primary tumors and peritoneal metastases. Significant 
differences based on average normalized mRNA expression ±SD between peritoneal 
metastases or primary tumors and matched uninjected ovaries were calculated using a two-
tailed Student’s t test. (C,D) Mouse IL-6 levels in the serum and ascitic fluid Arid1afl/fl;
(Gt)Rosa26Pik3ca*H1047R mice, as measured by anti-IL-6 ELISAs. Significant differences 
based on the average protein concentration ±SD between wild-type versus Arid1afl/fl;
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(Gt)Rosa26Pik3ca*H1047R mice were calculated using a two-tailed Student’s t test. (E) IL-6 
expression in an Arid1afl/fl;(Gt)Rosa26Pik3ca*H1047R tumor by IHC. (F) MTT absorbance 
values plotted with log antibody concentration (µg mL−1) for non-specific rat IgG-treated 
(control) or rat anti-mouse IL-6 treated Arid1afl/fl;(Gt)Rosa26Pik3ca*H1047R ascitic tumor 
cells after 96 hrs. of treatment. Plot represents the average absorbance value ±SD for 
treatment performed on three independent cell lines. Significant differences between 
control- and anti-IL-6-treated cells were calculated using a two-tailed Student’s t test 
(*significant p-value <0.05). (G) Primary ascitic tumor cells were treated 10, 1, 0.01, or 0 µg 
mL−1 rat anti-mouse IL-6 or non-specific Rat IgG-treated (control). (H,I) IL-6 expression in 
Arid1afl/fl;(Gt)Rosa26Pik3ca*H1047R ascitic tumor cells stably expressing control shRNAs 
or IL-6 shRNAs by ELISA and western blot. Each replicate represents in stable pool of IL-6 
shRNA expressing cells from three independently isolated tumor cell lines. Significant 
differences based on the average protein concentration ±SD between control- versus IL-6 
shRNA were calculated using a two-tailed Student’s t test. (J) MTT absorbance values 
plotted over time for control shRNA-, IL-6 shRNA-, or IL-6 shRNA-expressing cells 
supplemented with 10 ng/mL IL-6. Cells were plated at 2×10e4 cells per mL at hour 0, then 
MTT measurements were taken every 24 hours for a total of 96 hours. Significant 
differences between control- and IL-6-shRNA expressing cells were calculated using a two-
tailed Student’s t test (*significant p-value < 0.05). (K,L) Whole-mount images of control- 
and IL-6-shRNA tumorgrafts (arrowheads) on the right flank of nude mice and images of 
corresponding H&E-stained tumorgraft sections. (M) Plot of growth rates for control- and 
IL-6-shRNA expressing tumorgrafts over 21 days of measurement. Significant differences 
between control- and IL-6-shRNA tumorgraft growth rates were calculated using a two-
tailed Student’s t test. Only p-values <0.05 were considered significant.
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Figure 7. Coexistent ARID1A-PIK3CA mutations induce IL-6 expression in a cooperative 
manner
(A) IL-6 mRNA expression in AdCRE-infected primary OSE cells carrying all allele 
combinations. (B) Normalized IL-6 ELISA measurements of AdCRE-infected primary OSE 
cells carrying all allele combinations. Significant differences based on the average 
normalized expression value ±SD among mutant allele combinations versus wildtype were 
calculated using a two-tailed Student’s t test. (C) Western blot showing ARID1A, P-AKT 
S473, total AKT, P-STAT3 Y705, and total STAT3 levels in AdCRE-infected primary OSE 
cells carrying all allele combinations. AdCRE-infected wildtype cells served as controls. (D) 
MTT cell viability assay on primary Arid1afl/fl;(Gt)Rosa26Pik3ca*H1047R OSE cells treated 
with AdControl, AdCRE, or AdCRE supplemented with 5 µg mL−1 anti-IL-6 antibodies. (E) 
Treatment of normal (wild type) primary OSE cells with vehicle (v/v), 10 ng mL−1 IL-6, or 
10 ng mL−1 IL-6 supplemented with 5 µg mL−1 anti-IL-6 antibodies. Significant differences 
based on the average MTT absorbance value ±SD between three independent replicates of 
AdControl- versus AdCRE-infected or vehicle versus IL-6-treated cells were calculated 
using a two-tailed Student’s t test. (F) Western blot of normal primary OSE cells showing 
dose-dependent increases in P-STAT3 Y705 levels following IL-6 treatment. Co-treatment 
with 5 µg mL−1 anti-IL-6 antibodies blocked P-STAT3 Y705 induction. (G) ARID1A 
occupancy at the IL6 locus was detected by chromatin immunoprecipitation (ChIP) using 
anti-ARID1A antibodies (denoted as IP) on crosslinked chromatin from AdControl- or 
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AdCRE-infected Arid1afl/fl;(Gt)Rosa26Pik3ca*H1047R primary OSE cells. Non-specific 
isotype matched antibodies (denoted as NS) were used in control ChIPs. ARID1A 
occupancy at the IL6 promoter (site or primer pair B) is reduced in ARID1A depleted cells 
treated with AdCRE. Average percent ChIP input ±SD represent data from experiments 
performed using three primary OSE cell isolations. Significant differences were calculated 
using a two-tailed Student’s t test. (H) Proposed model of IL-6 regulation by ARID1A and 
PIK3CA mutations in OCCC. Only p-values <0.05 were considered significant.
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